Literature DB >> 26316860

Phenytoin Hypersensitivity: It's Time for Some Individuality.

Barry E Gidal.   

Abstract

Entities:  

Year:  2015        PMID： 26316860      PMCID： PMC4532225          DOI： 10.5698/1535-7511-15.4.177

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  9 in total

1.  Medical genetics: a marker for Stevens-Johnson syndrome.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

2.  HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese.

Authors:  Ying-Kit Cheung; Suk-Hang Cheng; Ernest J M Chan; Su V Lo; Margaret H L Ng; Patrick Kwan
Journal:  Epilepsia       Date:  2013-05-20       Impact factor: 5.864

3.  Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions.

Authors:  Zhibin Chen; Danny Liew; Patrick Kwan
Journal:  Neurology       Date:  2014-10-29       Impact factor: 9.910

4.  A new initiative on precision medicine.

Authors:  Francis S Collins; Harold Varmus
Journal:  N Engl J Med       Date:  2015-01-30       Impact factor: 91.245

5.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.

Authors:  Maja Mockenhaupt; John Messenheimer; Pat Tennis; Juergen Schlingmann
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

Review 6.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Authors:  Craig R Lee; Joyce A Goldstein; John A Pieper
Journal:  Pharmacogenetics       Date:  2002-04

7.  NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption.

Authors:  Sang-Heon Kim; Sang-Hoon Kim; Ho Joo Yoon; Dong Ho Shin; Sung Soo Park; Youn-Seup Kim; Jae-Seuk Park; Young Koo Jee
Journal:  Eur J Clin Pharmacol       Date:  2010-10-13       Impact factor: 2.953

8.  Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.

Authors:  Wen-Hung Chung; Wan-Chun Chang; Yun-Shien Lee; Ying-Ying Wu; Chih-Hsun Yang; Hsin-Chun Ho; Ming-Jing Chen; Jing-Yi Lin; Rosaline Chung-Yee Hui; Ji-Chen Ho; Wei-Ming Wu; Ting-Jui Chen; Tony Wu; Yih-Ru Wu; Mo-Song Hsih; Po-Hsun Tu; Chen-Nen Chang; Chien-Ning Hsu; Tsu-Lan Wu; Siew-Eng Choon; Chao-Kai Hsu; Der-Yuan Chen; Chin-San Liu; Ching-Yuang Lin; Nahoko Kaniwa; Yoshiro Saito; Yukitoshi Takahashi; Ryosuke Nakamura; Hiroaki Azukizawa; Yongyong Shi; Tzu-Hao Wang; Shiow-Shuh Chuang; Shih-Feng Tsai; Chee-Jen Chang; Yu-Sun Chang; Shuen-Iu Hung
Journal:  JAMA       Date:  2014-08-06       Impact factor: 56.272

9.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.